MiR-142-3p as a potential prognostic biomarker for esophageal squamous cell carcinoma
MiR-142-3p as a potential prognostic biomarker for esophageal squamous cell carcinoma
复制标题
DOI：
10.1002/jso.22066
复制
发表时间：
2012-02-01
影响因子：
2.5
通讯作者：
Xu, Li-Yan
中科院分区：
文献类型：
--
作者：
Lin, Rui-Jun;Xiao, Da-Wei;Xu, Li-Yan
背景与目的：microRNAs（miRNAs）是一种非编码小分子RNA，在包括人类肿瘤在内的多种疾病中都存在异常表达。本研究旨在检测hsa-miR-31、hsa-miR-142 - 3p、hsa-miR-3383p和hsa-miR-1261在食管鳞状细胞癌（esophageal squamous cell carcinoma，ESCC）中的表达，并探讨其临床意义。结果：miR-31和miR-142 - 3p在食管鳞癌中的表达与食管鳞癌的组织学分化程度有关（P <0.05，学生t检验）;在所有91例ESCC患者中，miR142 - 3p高表达与不良预后相关（P 0.014，对数秩），并被确定为ESCC的独立预后因素（P 0.017，单变量考克斯; P 0.022，多变量考克斯）。结论：miR-142 - 3p在食管鳞癌的发生发展中起重要作用，可能是食管鳞癌患者预后不良的生物标志物。外科肿瘤学杂志2012; 105：175 - 182. (C)2011 Wiley Periodicals，Inc.
Background and Objectives: microRNAs (miRNAs), small non-coding RNAs, are always aberrantly expressed in many diseases including human cancers. The aim of this study was to examine and determine the clinical significance of hsa-miR-31, hsa-miR-142-3p, hsa-miR-3383p, and hsa-miR-1261 expression in esophageal squamous cell carcinoma (ESCC).Methods: Expression levels of four selected miRNAs, initially evaluated by microarray, were validated by qRT-PCR. Various statistical methods were used to analyze the relationship between miRNA expression and clinicopathologic features and prognosis in 91 patients with ESCC.Results: MiR-31 and miR-142-3p expression were correlated to histological differentiation in ESCC (P < 0.05, Student's t-test); high miR142-3p expression was associated with a poor prognosis in all 91 ESCC patients (P 0.014, log-rank) and identified as an independent prognostic factor in ESCC (P 0.017, univariate Cox; P 0.022, multivariate Cox). More importantly, stratified analysis indicated that high miR-142-3p expression was correlated to a poor prognosis within good-prognosis groups comprised of ESCC patients with small tumor size, negative lymph node metastasis, or early stage (all P < 0.05).Conclusion: The main findings suggest that miR-142-3p is involved in the progression of ESCC and is a potential prognostic biomarker for ESCC. J. Surg. Oncol. 2012; 105: 175-182. (C) 2011 Wiley Periodicals, Inc.